Arcutis stock falls after Q3 earnings miss (ARQT:NASDAQ)

Arcutis Biotherapeutics (ARQT) reported Q3 2026 earnings that missed estimates due to higher expenses, causing its stock to drop 20%. Revenue rose 45% YoY to $143.9M, exceeding consensus by $1.3M, according to the company.

Original reporting
Published Nov 5, 2026, 4:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 5:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARQT
Bearish
high confidence
Mentioned
$ARQT
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ARQTBearishHigh
01

Why it matters

The earnings miss triggered a near 20% stock decline, indicating immediate downside risk.

02

Market read

The surprise earnings shortfall provides a clear short-term trading signal for ARQT.

03

What to watch

Potential pipeline milestones not covered in the brief could offset short-term weakness.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

Arcutis Biotherapeutics is a dermatology-focused biotech listed on NASDAQ.

Company-level read

Ticker impact

$ARQTBearishHigh confidence
Context

Arcutis reported Q3 earnings miss, shares fell ~20% after results showed higher expenses and revenue $143.9M.

Expected impact

downward pressure as market prices in the earnings shortfall

Evidence & confidence

Revenue beat was modest while expenses surprised to the upside, leading to a sharp share decline.

Market effects

Dermatology biotech sector may see broader risk reassessment.

US biotech indices could dip slightly.

Limited to investors in biotech and small-cap US equities.

Counterpoint

Revenue beat could suggest upside if expense growth is temporary.

Key entities

  • Arcutis Biotherapeutics

    NASDAQ-listed biotech reporting Q3 2026 results.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.